Table 1 Main characteristics of base editing systems
From: Genome scale analysis of pathogenic variants targetable for single base editing
Name | Cas protein | Deaminase | PAM | Editing window | Editing Efficiency | Reference: Pubmed ID (Author, Year) | Edited mutated nucleotides |
|---|---|---|---|---|---|---|---|
APOBEC | dCas9 | APOBEC1 | NGG | −18 to −11 | 15–75% | 27,096,365 (Komor, 2016) [6] | |
SaBE3 | SaCas9n | APOBEC1 | NNGRRT | −15 to −9 | 5–65% | T > C | |
SaKKH-BE3 | dCas9 | APOBEC1 | NNNRRT | −17 to −9 | 10–65% | 28,191,901 (Kim, 2017) [7] | |
EQR-Cas9 | dCas9 | APOBEC1 | NGAG | − 17 to − 10 | 10–40% | ||
VRER-Cas9 | dCas9 | APOBEC1 | NGCG | −19 to −10 | 10–35% | ||
VQR-Cas9 | dCas9 | APOBEC1 | NGAN | −17 to −10 | 10–60% | ||
YE1-VQR-Cas9 | dCas9 | APOBEC1 | NGAN | −16 to −15 | 10–30% | ||
A-BE3 | dCas9 | APOBEC1 | NGG | −17 to −12 | 20–50% | ||
Y-BE3 | dCas9 | APOBEC1 | NGG | −17 to −13 | 10–30% | ||
FE-BE3 | dCas9 | APOBEC1 | NGG | −16 to −14 | 10–40% | ||
YEE-BE3 | dCas9 | APOBEC1 | NGG | −16 to −15 | 5–35% | ||
PmCDA1 | nCas9 | PmCDA1 | NGG | −20 to −16 | 6–96% | 27,492,474 (Nishida, 2016) [8] | |
BE-PLUS | nCas9 | APOBEC1 | NGG | −16 to −5 | 10–30% | 29,875,396 (Jiang, 2018) [9] | |
xCas9–BE3 | xCas9 | APOBEC1 | NGN, GAW | −17 to −13 | 10–24% | 29,512,652 (Hu, 2018) [10] | |
dCpf1-eBE | dCpf1 | APOBEC1 | TTTV | 8 to 13 | 15–30% | 29,553,573 (Li, 2018) [11] | |
dCpf1-eBE-YE | dCpf1 | APOBEC1 | TTTV | 10 to 12 | 2–28% | ||
APOBEC3A-Cas9 | nCas9 | APOBEC3A | NGG | −16 to −12 | 16–48% | 30,059,493 (Gehrke, 2018) [12] | |
EA3A-BE3(VRQR) | xCas9 | APOBEC3A | NGAN | −17 to −10 | 15–63% | ||
EA3A-BE3(xCas9) | xCas9 | APOBEC3A | NGG, NGT | −17 to −13 | 17–35% | ||
BE-PAPAPAP | nCas9 | APOBEC1 | NGG | −16 to −15 | 24% | 30,683,865 (Tan, 2019) [13] | |
cCDA1-BE3 | nCas9 | CDA1 | NGG | −19 to − 16 | 50% | ||
xCas9–ABE | xCas9 | TadA | NGV, GAT | −17 to −13 | 16–69% | 29,512,652 (Hu, 2018) [10] | G > A |
TadA | dCas9 | TadA | NGG | −17 to −12 | 25–75% | 29,160,308 (Gaudelli, 2017) [14] |